JPRN-UMIN000009634已完成2 期
Phase II/III study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemotherapy for resectable pancreatic cancer (Prep-02/JSAP-05) - Neoadjuvant GS therapy for pancreatic cancer : Prep-02/JSAP-05
Study group of preoperative therapy for pancreatic cancer (PREP)/Japanese Study Group of Adjuvant Therapy for pancreatic Cancer (JSAP)0 个研究点目标入组 364 人开始时间: 2012年12月26日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 364
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) pulmonary fibrosis or interstitial pneumonitis 2) Uncontrolled watery diarrhea 3) Active double cancer 4) Active infection 5) HBs antigen positive 6) Pregnant females, possibly pregnant females
研究者
相似试验
招募中
1 期
Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)Borderline resectable pancreatic cancerJPRN-UMIN000014498Study group of preoperative therapy for pancreatic cancer (PREP)40
招募中
1 期
Prep-03C535836Pancreatic cancerpancreatic cancerJPRN-jRCTs021180045nno Michiaki40
已完成
2 期
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25
已完成
2 期
Phase II study of gemcitabine and S-1 combination therapy in advanced pancreatic cancer with malignant ascites.pancreatic cancer with ascitesJPRN-UMIN000003269ational Cancer Center Hospital East Hepatobiliary and Pancreatic Oncology Division36
已完成
2 期
Randomized phase II study of Gemcitabine and S-1 combination therapy versus S-1 in patients with Gemcitabine-refractory unresectable advanced Pancreatic Cancerunresectable advanced Pancreatic CancerJPRN-UMIN000011806Osaka Pancreas Forum49